Adial Pharmaceuticals, Inc. — Q2 2023 Form 10-Q
Reporting period: Three and six months ended June 30, 2023. Adial is a clinical-stage biopharmaceutical company developing AD04 for alcohol use disorder (AUD); it has no approved products and reported no product revenue. On June 30, 2023, it completed the sale of its Purnovate subsidiary to Adovate, a related party. Financial statements are unaudited.
Financial results and position
| Metric | Q2 2023 / June 30, 2023 | Comparable period / prior year-end |
|---|---|---|
| Revenue | No product revenue | No product revenue reported |
| Continuing-operations loss | $1.51 million for Q2; $3.75 million for H1 | $3.24 million for Q2 2022; $5.70 million for H1 2022 |
| Net income (loss) | $1.09 million income for Q2; $1.82 million loss for H1 | $3.85 million loss for Q2 2022; $6.76 million loss for H1 2022 |
| Operating expenses | $1.48 million for Q2; $3.75 million for H1 | $3.24 million for Q2 2022; $5.71 million for H1 2022 |
| Cash and cash equivalents | $1.22 million | $4.00 million at December 31, 2022 |
| Total assets / liabilities | $3.78 million / $0.46 million | $5.73 million / $2.46 million at December 31, 2022 |
| Stockholders’ equity | $3.32 million | $3.28 million at December 31, 2022 |
| Cash flow, H1 | Operating: $(4.19) million; investing: $0.80 million; financing: $0.61 million | Operating: $(6.03) million; investing: $0; financing: $9.13 million in H1 2022 |
Q2 net income reflects a $2.66 million one-time gain on the Purnovate sale; it does not indicate operating profitability. The filing reports no debt balance. Product margins are not applicable because the company has no product sales.
Material changes and transactions
- Operating expenses fell 54% in Q2 year over year, primarily due to lower general and administrative costs, reduced equity compensation, and winding down clinical-trial activity. H1 operating expenses fell 34%; R&D rose 10% as regulatory consulting and final CRO costs increased, while G&A declined 41%.
- Purnovate sale consideration totaled approximately $3.27 million: $800,000 cash received, a 19.9% Adovate equity interest valued at $1.73 million, and $737,276 of estimated expense reimbursements receivable. The filing says about $740,000 in additional reimbursements was expected in Q3 2023. Contingent milestone and royalty payments were assigned no balance-sheet value.
- Adovate is a related party: its CEO and founder is an Adial director and former Adial CEO. Adial accounts for its 19.9% interest under the equity method and records its share of Adovate results on a one-quarter lag.
- In February, Adial raised $609,613 net from a registered stock sale. Its May standby equity purchase agreement with Alumni Capital permits up to $3 million of share sales, with the company able to increase the commitment to $10 million subject to agreement terms. Shares are priced at 95% of the lowest daily VWAP over the three days after a purchase notice; no notices had been issued by June 30. The filing also describes Nasdaq issuance limits.
Liquidity, outlook, and risks
- Going concern: Management states cash is insufficient to fund operations for the 12 months following filing and that substantial doubt exists about the company’s ability to continue as a going concern. After the Purnovate sale, fee, and expected reimbursements, management estimated funds could support operations into Q1 2024, but additional capital is required.
- Management said it expects to pursue two further Phase 3 trials for AD04, estimated to cost about $25 million in total, and was in discussions with potential commercial partners. The filing provides no committed financing or assurance that funding or partnerships will be obtained. Without funding, trials or other R&D could be delayed, reduced, or discontinued.
- The company’s current plan targets commercialization in 2026 or later, subject to further development and regulatory approval. AD04’s development path follows the ONWARD Phase 3 trial; the filing reports regulatory consultations in the U.S. and Europe, but no product approval.
- Risks include clinical and regulatory uncertainty, capital access and potential shareholder dilution, and Nasdaq listing compliance. The company effected a 1-for-25 reverse stock split on August 4, 2023; it did not assure continued compliance. The filing notes earlier minimum-bid-price and stockholders’ equity deficiencies.
- Management reported material weaknesses in financial reporting controls, including inadequate risk assessment and documentation, approval and review processes, GAAP expertise, IT controls, and segregation of duties. Management concluded disclosure controls were not effective at quarter-end.
- The filing reports approximately $412,000 of future commitments under other consulting and vendor agreements and no pending material legal actions. UVA license terms include annual minimum royalties, development milestones, royalties on future sales, and a 15% share of sublicensing income.
Most important facts to verify
- Whether Adovate paid the approximately $737,000 reimbursement receivable on the expected schedule, and the status and valuation of Adial’s Adovate equity interest.
- Adial’s current cash runway, cash burn after the Purnovate transfer, and any subsequent financing, partnership, or licensing agreements.
- The regulatory plan and requirements for AD04, including whether two Phase 3 trials are required, their funding, timing, and estimated cost.
- Current Nasdaq listing compliance and any further effects of the reverse split or the Alumni Capital equity facility.
- Progress in remediating the disclosed internal-control material weaknesses and the resulting impact on reporting reliability.